Alllife Medicine

Alllife Medicine, also known as Huahao Zhongyuan, is a biopharmaceutical company headquartered in Beijing, China, dedicated to the discovery and development of innovative anti-cancer drugs. The company utilizes a proprietary synthetic biology platform to develop therapeutics derived from microbial secondary metabolites, specifically focusing on epothilone analogs. Its flagship product, Utidelone (UTD1), is a genetically engineered microtubule stabilizer that has been approved in China for the treatment of metastatic breast cancer. Alllife Medicine is currently expanding its pipeline with oral formulations of Utidelone and other candidates targeting various solid tumors, including non-small cell lung cancer and brain metastases. The company's technology platform integrates metabolic engineering and high-throughput screening to optimize natural products for clinical use. With a focus on addressing unmet medical needs in oncology, Alllife Medicine aims to provide more effective and less toxic treatment options for cancer patients globally.